78 related articles for article (PubMed ID: 27396204)
1. Chlorogenic Acid Interaction with Cisplatin and Oxaliplatin: Studies in Cervical Carcinoma Cells.
Catanzaro D; Filippini R; Vianello C; Carrara M; Ragazzi E; Montopoli M
Nat Prod Commun; 2016 Apr; 11(4):499-502. PubMed ID: 27396204
[TBL] [Abstract][Full Text] [Related]
2. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency.
Martelli L; Ragazzi E; Di Mario F; Basato M; Martelli M
Anticancer Res; 2009 Oct; 29(10):3931-7. PubMed ID: 19846931
[TBL] [Abstract][Full Text] [Related]
4. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
Stordal B; Peters G; Davey R
Genes Chromosomes Cancer; 2006 Dec; 45(12):1094-105. PubMed ID: 16967470
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
6. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin activity in head and neck cancer cell lines.
Espinosa M; Martinez M; Aguilar JL; Mota A; De la Garza JG; Maldonado V; Meléndez-Zajgla J
Cancer Chemother Pharmacol; 2005 Mar; 55(3):301-5. PubMed ID: 15619139
[TBL] [Abstract][Full Text] [Related]
8. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells.
Rave-Fränk M; Schmidberger H; Christiansen H; Boll C; Lehmann J; Weiss E
Int J Radiat Biol; 2007 Jan; 83(1):41-7. PubMed ID: 17357438
[TBL] [Abstract][Full Text] [Related]
11. Effect of 41 degrees C and 43 degrees C on cisplatin radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin.
Bergs JW; Haveman J; Ten Cate R; Medema JP; Franken NA; Van Bree C
Oncol Rep; 2007 Jul; 18(1):219-26. PubMed ID: 17549371
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
Stordal B; Pavlakis N; Davey R
Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
[TBL] [Abstract][Full Text] [Related]
13. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):109-14. PubMed ID: 9220289
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of oxaliplatin in neuroblastoma cell lines.
Riccardi A; Ferlini C; Meco D; Mastrangelo R; Scambia G; Riccardi R
Eur J Cancer; 1999 Jan; 35(1):86-90. PubMed ID: 10211093
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
17. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
18. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
19. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
